Opportunity Information: Apply for TI 15 007
Apply for TI 15 007
- The Substance Abuse Mental Health Services Adminis. in the health sector is offering a public funding opportunity titled "Targeted Capacity Expansion Medication Assisted Treatment Prescription Drug and Opioid Addiction (MAT PDOA) grants" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.243 Substance Abuse and Mental Health ServicesProjects of Regional and National Significance.
- This funding opportunity was created on Mar 5, 2015 and posted on Feb 26, 2015.
- Applicants must submit their applications by May 8, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $11,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 11 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligibility is limited to 39 states identified with having the highest rates of primary treatment admissions for heroin and opioids per capita, as identified by SAMHSA s Treatment Episode Data Set (TEDS) 2002 2012(1), (see Appendix IV for a list of eligible states). The application must be submitted by the Single State Agency (SSA) for Substance Abuse within the state. Eligibility has been limited to these states because SAMHSA strongly believes that these 39 states represent the highest rates of primary treatment admissions with heroin and opiates per capita. In addition, SAMHSA has identified 18 of these states that have demonstrated a dramatic increase in admissions for the treatment of opiates and heroin in recent years and will be given priority for funding. This approach is consistent with the language used to describe the program in the Committee Report accompanying the FY 2015 Consolidated Appropriations Bill. (1)Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS) 2002 2012. State Admissions to Substance Abuse Treatment Services. BHSIS Series S 72, HHS Publication No. (SMA) 14 4889. Rockville, MD Substance Abuse and Mental Health Services Administration, 2014.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Targeted Capacity Expansion Medication Assisted Treatment Prescription Drug and Opioid Addiction (MAT PDOA) grants were a SAMHSA discretionary grant program designed to help states strengthen and expand their opioid use disorder treatment systems, with a clear emphasis on medication assisted treatment (MAT) paired with comprehensive services. The central idea was to increase statewide capacity so more people could access timely, effective, coordinated care, including evidence based medications and recovery supports. SAMHSA framed the program around improving access and quality, not just adding isolated services, by encouraging organized systems that connect medical care, behavioral health treatment, and social and recovery supports.
The program spelled out three main outcome goals SAMHSA wanted grantees to drive and measure: increasing the number of individuals receiving MAT using FDA approved pharmacotherapies for opioid use disorder, increasing the number of individuals receiving integrated care, and reducing illicit drug use at a six month follow up point. For this funding opportunity, "integrated care" meant the organized delivery and/or coordination of medical, behavioral, social, and recovery support services so that individuals with multiple needs experience better overall health outcomes. This definition matters because it signals that SAMHSA was looking for systems where services are connected and coordinated rather than fragmented, with attention to the whole person and the reality that many people with opioid use disorder also have co-occurring health and social needs.
MAT, as defined in the announcement, specifically referred to FDA approved opioid agonist medications such as methadone and buprenorphine products (including buprenorphine/naloxone combination formulations and buprenorphine mono products) used for maintenance treatment, as well as opioid antagonist medications like naltrexone (including extended release and oral forms) used to prevent relapse. The solicitation also clarified that MAT was not limited to prescribing medication; it included screening and assessment (including determining opioid use disorder severity, physical dependence, and appropriateness for MAT) and case management. SAMHSA also emphasized that MAT should be delivered alongside comprehensive substance use disorder treatment, including counseling and behavioral therapies, and when appropriate, pharmacotherapy for co-occurring alcohol use disorder. Overall, the program pushed a clinically driven, person centered, individualized approach rather than a one size fits all model.
Eligibility and targeting were strongly shaped by data on treatment admissions. Only 39 states identified as having the highest rates of primary treatment admissions for heroin and opioids per capita, based on SAMHSA's Treatment Episode Data Set (TEDS) 2002 to 2012, were eligible to apply (the eligible states were listed in the program appendices). The application had to be submitted by the state's Single State Agency (SSA) for Substance Abuse, which effectively limited applicants to the official state authority responsible for administering substance use disorder systems and funds. SAMHSA justified this approach by stating that these states represented the highest per capita rates of admissions for heroin and other opiates, aligning the funding with jurisdictions experiencing the most intense burden as reflected in admissions data.
Within the eligible pool, SAMHSA also built in a priority preference for a subset of states experiencing not only high admission rates but also a sharp increase in admissions over time. Specifically, 18 states identified as having dramatic increases in admissions were to receive priority, and priority states had to document that their rate of change in primary treatment admissions for heroin and non-heroin opiates from 2007 to 2012 was 50 percent or greater. To receive that priority consideration, applicants needed to include a confirming statement and supporting documentation in a required application attachment (Attachment 5). In other words, the program used both level (high per capita admissions) and trend (rapid growth) to focus attention on states where the opioid crisis appeared to be accelerating.
On the funding mechanics, this was a grant program (not a loan or cooperative agreement) under CFDA 93.243, categorized under health and framed as part of SAMHSA's "Projects of Regional and National Significance." SAMHSA expected to make 11 awards, with an estimated total funding amount of $11,000,000. The award ceiling was $1,000,000, there was no stated award floor, and the program did not require cost sharing or matching funds, which can be significant for state agencies trying to expand services quickly without needing to secure additional matching dollars.
Administratively, the funding opportunity number was TI-15-007, it was posted on February 26, 2015, and the application deadline was May 8, 2015, with an archive date of June 7, 2015. SAMHSA tied the effort to its broader Strategic Initiative on the Prevention of Substance Abuse and Mental Illness, positioning MAT expansion and integrated care as core strategies for addressing opioid use disorder and reducing harm. For applicants needing assistance accessing the full announcement, the listed grants management contact was Eileen Bermudez at SAMHSA's Office of Financial Resources, Division of Grants Management.
Frequently Asked Questions (FAQs)
What is the Targeted Capacity Expansion Medication Assisted Treatment Prescription Drug and Opioid Addiction (MAT PDOA) grant program?
MAT PDOA was a SAMHSA discretionary grant program designed to help states strengthen and expand their opioid use disorder (OUD) treatment systems. It focused on increasing statewide capacity so more people could access timely, effective, coordinated care, with a clear emphasis on medication assisted treatment (MAT) paired with comprehensive services and recovery supports.
What problem was SAMHSA trying to address through this program?
The program aimed to improve access to and quality of OUD treatment at a system level, not just by adding isolated services. SAMHSA emphasized organized, connected systems that link medical care, behavioral health treatment, and social and recovery supports so care is coordinated rather than fragmented.
What were the main outcome goals grantees were expected to pursue and measure?
SAMHSA identified three primary outcome goals:
- Increase the number of individuals receiving MAT using FDA approved pharmacotherapies for opioid use disorder.
- Increase the number of individuals receiving integrated care.
- Reduce illicit drug use at a six-month follow-up point.
How did the grant define "integrated care"?
For this opportunity, "integrated care" meant the organized delivery and/or coordination of medical, behavioral, social, and recovery support services so that individuals with multiple needs experience better overall health outcomes. The emphasis was on connected and coordinated services, recognizing that many people with OUD have co-occurring health and social needs.
What did SAMHSA mean by medication assisted treatment (MAT) in this program?
MAT referred to the use of FDA approved pharmacotherapies for OUD, including opioid agonist medications used for maintenance treatment and opioid antagonist medications used to prevent relapse. SAMHSA also clarified that MAT was not limited to prescribing medication; it included related clinical and service components such as screening, assessment, and case management, and it was intended to be delivered alongside comprehensive substance use disorder treatment.
Which medications were specifically included under MAT for this grant?
The announcement specifically referenced:
- Opioid agonist medications such as methadone and buprenorphine products, including buprenorphine/naloxone combination formulations and buprenorphine mono products, used for maintenance treatment.
- Opioid antagonist medications like naltrexone, including extended release and oral forms, used to prevent relapse.
Was MAT limited to medication prescribing under this funding opportunity?
No. The solicitation stated that MAT included screening and assessment (including determining OUD severity, physical dependence, and appropriateness for MAT) and case management. SAMHSA emphasized that MAT should be paired with comprehensive substance use disorder treatment such as counseling and behavioral therapies.
Did the program address co-occurring conditions or related treatment needs?
Yes. SAMHSA emphasized comprehensive services delivered alongside MAT, including counseling and behavioral therapies, and noted that, when appropriate, applicants should include pharmacotherapy for co-occurring alcohol use disorder.
Who was eligible to apply for MAT PDOA funding?
Eligibility was limited to 39 states identified as having the highest rates of primary treatment admissions for heroin and opioids per capita, based on SAMHSA's Treatment Episode Data Set (TEDS) data from 2002 to 2012. The eligible states were listed in the program appendices.
What type of applicant could submit the application for an eligible state?
The application had to be submitted by the state's Single State Agency (SSA) for Substance Abuse. This requirement effectively limited applicants to the official state authority responsible for administering the substance use disorder system and related funding.
How did SAMHSA determine which states were eligible?
SAMHSA based eligibility on per-capita rates of primary treatment admissions for heroin and other opioids, using TEDS data from 2002 to 2012. SAMHSA stated that this targeted jurisdictions experiencing the most intense burden as reflected in admissions data.
Was there a priority preference within the eligible states?
Yes. SAMHSA provided a priority preference for 18 states identified as having dramatic increases in admissions over time, not just high admission rates.
What qualified a state for priority preference consideration?
Priority states had to document that their rate of change in primary treatment admissions for heroin and non-heroin opiates from 2007 to 2012 was 50 percent or greater.
What did applicants need to submit to receive priority preference consideration?
Applicants seeking priority needed to include a confirming statement and supporting documentation in a required application attachment (Attachment 5).
What was the funding opportunity number for this grant?
The funding opportunity number was TI-15-007.
What was the CFDA number and how was the program categorized?
The program was listed under CFDA 93.243. It was categorized under health and framed as part of SAMHSA's "Projects of Regional and National Significance."
Was this funding a grant, a loan, or a cooperative agreement?
This opportunity was a grant program (not a loan or cooperative agreement).
How many awards did SAMHSA expect to make and what was the total estimated funding?
SAMHSA expected to make 11 awards with an estimated total funding amount of $11,000,000.
What was the maximum award amount per grantee?
The award ceiling was $1,000,000.
Was there a minimum award amount stated?
No stated award floor was provided in the information described for this opportunity.
Did the program require cost sharing or matching funds?
No. The program did not require cost sharing or matching funds.
When was the opportunity posted and what were the key dates?
The opportunity was posted on February 26, 2015. The application deadline was May 8, 2015, and the archive date was June 7, 2015.
How did SAMHSA position this grant within its broader goals?
SAMHSA tied the effort to its Strategic Initiative on the Prevention of Substance Abuse and Mental Illness, positioning MAT expansion and integrated care as core strategies for addressing opioid use disorder and reducing harm.
Who was the listed grants management contact for help with the full announcement?
The listed grants management contact was Eileen Bermudez at SAMHSA's Office of Financial Resources, Division of Grants Management.
Browse more opportunities from the same category: Health
Next opportunity: Childrens Health Exposure Analysis Resource (CHEAR) National Exposure Assessment Laboratory Network (U2C)
Previous opportunity: Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for TI 15 007
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (TI 15 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Consumer and Consumer Supporter Technical Assistance Centers (Short Title Consumer and Consumer Supporter TA Centers) Apply for SM 15 011 Funding Number: SM 15 011 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $335,600 |
| Ryan White HIV/AIDS Part C Capacity Development Program Apply for HRSA 15 024 Funding Number: HRSA 15 024 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| One Year Administrative Supplements to NIMH supported Research for FY2015 (Admin Supp) Apply for PA 15 128 Funding Number: PA 15 128 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening and Improving the HIV Care Continuum within Ryan White HIV/AIDS Program Part A Jurisdictions Apply for HRSA 15 113 Funding Number: HRSA 15 113 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Association for Public Health Statistics and Information Systems (NAPHSIS) National Environmental Public Health Tracking Network Apply for CDC RFA EH15 1501 Funding Number: CDC RFA EH15 1501 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $125,000 |
| Mobilizing Research A Research Resource to Enhance mHealth Research (U2C) Apply for RFA OD 15 129 Funding Number: RFA OD 15 129 Agency: National Institutes of Health Category: Health Funding Amount: $1,250,000 |
| Paul Coverdell National Acute Stroke Prevention Apply for CDC RFA DP15 1514 Funding Number: CDC RFA DP15 1514 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Now is the Time Project AWARE Community Apply for SM 15 012 Funding Number: SM 15 012 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $125,000 |
| Consolidated and Further Continuing Appropriations Act, 2015 Health Infrastructure Investment Program Apply for HRSA 15 129 Funding Number: HRSA 15 129 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,000,000 |
| Global Infectious Disease Research Administration Development Award for Low and Middle Income Country Institutions (G11) Apply for PAR 15 131 Funding Number: PAR 15 131 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| FY15 College Sexual Assault Policy and Prevention Initiative Apply for WH AST 15 002 Funding Number: WH AST 15 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $300,000 |
| Investigations on Primary Immunodeficiency Diseases (R01) Apply for PAR 15 130 Funding Number: PAR 15 130 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| US Ambassadors HIV and AIDS Community Grant Apply for USEMBASSYSA COMMUNITYGRANTS 2015 Funding Number: USEMBASSYSA COMMUNITYGRANTS 2015 Agency: U.S. Mission to South Africa Category: Health Funding Amount: $30,000 |
| NEI Administrative Supplements to Small Business Innovative Research (SBIR) Grants for the Procurement of Expertise in the Federal Regulatory Approval Process for New Drugs and/or Devices (Admin Supp) Apply for PA 15 132 Funding Number: PA 15 132 Agency: National Institutes of Health Category: Health Funding Amount: $25,000 |
| Biological and Physiological Effects of E cigarette Aerosol Mixtures (R01) Apply for RFA DE 16 004 Funding Number: RFA DE 16 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Biological and Physiological Effects of E cigarette Aerosol Mixtures (R21) Apply for RFA DE 16 005 Funding Number: RFA DE 16 005 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| USAID/Zambia Community HIV Prevention Project (Z CHPP) Apply for RFA 611 15 000010 Funding Number: RFA 611 15 000010 Agency: Zambia USAID Lusaka Category: Health Funding Amount: $24,990,000 |
| Validation of Pediatric Patient Reported Outcomes in Chronic Diseases (PEPR) Consortium (U19) Apply for RFA AR 15 014 Funding Number: RFA AR 15 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition National Biocontainment Laboratories (NBLs) Operations Support (UC7) Apply for RFA AI 15 009 Funding Number: RFA AI 15 009 Agency: National Institutes of Health Category: Health Funding Amount: $11,500,000 |
| Maternal and Child Health Epidemiology National and State Coalition Capacity Building to Improve Outcomes Apply for CDC RFA DP15 1507 Funding Number: CDC RFA DP15 1507 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,875,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "TI 15 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.